Interventional technology developer AngioDynamics has posted financial results for the first quarter of 2019 (end-August 31), reporting flat sales compared with the same period last year.
The company had sales of $85.3 million, compared with $85.4 million in its first quarter of 2018. Sales for its oncology division were down 6.1%, from $12.3 million in the first quarter of 2018 to $11.6 million for the first quarter of 2019.
The firm's net loss for the period was $469,000, compared with a net loss of $35,000 during the same period in 2018.
